VRTX has recorded a positive one-day return after earnings in 58% of instances. When the return is positive, the median ...

The stock's fall snapped a seven-day winning streak.

IgA nephropathy (IgAN) is an autoimmune disorder that affects the kidneys by impairing the filtration function of the small ...

Vertex AI souped up, Ironwood TPU, agent SDK and Cloud WAN for companies: These are just some of the highlights from the ...

Brown, playing only his third Korn Ferry Tour event, birdied five of his last six holes in a back nine of seven-under 29 in the Veritex Bank Championship at Texas Rangers Golf Club in Arlington, Tex., ...

Vertex Pharmaceuticals (VRTX) shares have climbed 22.3% year-to-date, significantly outpacing the S&P 500 and broader healthcare sector ...

Google has a new open-source developer kit and protocol on offer that should make it easier for AI agents to express their ...

As previously reported, Cantor Fitzgerald assumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and a price target of ...

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 2.37% to $477.52 Monday, on what proved to be an all-around dismal trading ...

ToolGen commences legal action in UK court over Vertex's genome editing therapy, CASGEVY ®Seeks to expand licensing of its proprietary CRISPR RNP technologySEOUL, South Korea, April 21, 2025 /PRNewswi ...

ToolGen, Inc. (KOSDAQ 199800), led by CEO Jong Sang Ryu and recognized as a global leader in genome editing technology, announced today that it has filed a patent infringement lawsuit in the United ...